Nav: Home

New therapeutic approach for advanced lung disease

January 12, 2018

The study was a cooperative effort between the team headed by assistant professor Dr Jürgen Knobloch from the Medical Clinic III for Pneumology, Sleep and Respiratory Medicine at the Bergmannsheil University Hospital in Bochum, Germany, and Prof Dr Andrea Koch, member of the German Center for Lung Research (DZL), previously in Bochum, now at the Medical Clinic V for Pneumology at the LMU University Hospital in Munich, as well as a team from the company RespiVert Ltd, a subsidiary of Janssen Biotech Inc., and Prof Dr Erich Stoelben from the Lung Clinic in Köln-Merheim. According to the authors of the study, the new substances may potentially constitute a breakthrough in the treatment of COPD.

New drug candidates reduce inflammation

COPD patients suffer from chronic inflammation of the respiratory tract. Certain enzymes, so-called protein kinases, regulate the inflammation process. They are indirectly over-activated due to smoking, due to pro-inflammatory factors characteristic of COPD, and due to respiratory infections. This results in the production of even more pro-inflammatory factors, which, in turns, promotes disease progression.

According to the researchers, Narrow Spectrum Kinase Inhibitors, i.e. NSKI, that inhibit protein kinases constitute a promising therapy approach. Two NSKIs - namely RV1088 und RV568, which were identified and provided by RespiVert for the studies - were tested by the team in cell cultures; the researchers compared their efficacy with a conventional corticosteroid and various Single Protein Kinase Inhibitors, which are likewise considered potential drug candidates. The NSKIs were more effective in decelerating the production of inflammatory agents than any of the reference substances.

Effect of other substances not sufficient

A number of small molecule inhibitors of specific single kinases have previously been successfully tested in preclinical trials and advanced to clinical studies. These substances selectively inhibit individual protein kinases or a family of protein kinases. "However, it is emerging that the effect would not be sufficient in clinical applications," explains Jürgen Knobloch, head of laboratory at the Pneumology Clinic at Bergmannsheil. "In case of such a specific inhibition, activation of other protein kinases may act to induce similar inflammation."

Therefore, the team tested new drug candidates that target not only one protein kinase or a family of protein kinases, but a specific spectrum of several protein kinase families. In the research lab at the Bergmannsheil Pneumology Clinic, researchers then tested the substances in primary cultures of airway smooth muscle cells taken from COPD patients.

Potentially transferable to clinical applications

"Our study has demonstrated that NSKIs are promising candidates for the development of urgently required anti-inflammatory COPD therapies," says Jürgen Knobloch. Consequently, he and his colleagues believe that the findings gained in the preclinical model offer an immense potential for a transfer to applications in patient care.

According to expert estimates, COPD currently affects 11.7 percent of the global population. In most cases, the disease starts as chronic bronchitis, and it is mainly caused by smoking tobacco. Current therapies can retard the progression of COPD and provide symptom relief, but they cannot stop it. With the exception of one drug that is used for the treatment of very severe COPD in a subset of the COPD population, there are currently no other approved non-steroidal therapies that target inflammation, which is central for the progression of COPD. Currently available inhaled corticosteroids help alleviate the symptoms of other chronic inflammatory pulmonary diseases and provide some benefit in the prevention of acute exacerbations, but they are currently only recommended for use in combination with bronchodilators and in patients that experience frequent exacerbations.

Clinical Studies in progress

The substances identified in this study are currently being developed further by a pharmaceutical company in a clinical programme, as part of a translational effort to bring these compounds forward for patients.
-end-
Original publication

Jürgen Knobloch, David Jungck, Catherine Charron, Erich Stoelben, Kazuhiro Ito, Andrea Koch: Superior anti-inflammatory effects of Narrow spectrum kinase inhibitors in airway smooth muscle cells from subjects with chronic obstructive pulmonary disease, in: Journal of Allergy and Clinical Immunology, 2017, DOI: 10.1016/j.jaci.2017.09.026 http://www.jacionline.org/article/S0091-6749(17)31623-8/abstract

Press Contact

Assistant Professor Dr Jürgen Knobloch
Head of Laboratory
Medizinische Klinik III für Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin
Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil
Phone: +49 234 302 3404
Email: juergen.knobloch@bergmannsheil.de

Professor Dr Andrea Koch
Head of the research group Obstructive Pulmonary Diseases and of CPC-Studienambulanz, Helmholtz-Zentrum Munich
Member of the German Center for Lung Research (DZL) Munich
Med. Klinik & Poliklinik V
Klinikum der LMU München
Phone: +49 89 4400 75310
Email: andrea.koch@med.uni-muenchen.de

Robin Jopp
Head of the Corporate Communications Strategic Unit
Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil gGmbH
Bürkle-de-la-Camp-Platz 1
44789 Bochum
Phone: +49 234 302 6125
Email: robin.jopp@bergmannsheil.de

About Bergmannsheil

Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil is one of the largest urgent care clinics for maximum treatment in the Ruhr area. Founded in 1890 as the world's first Accident and Emergency clinic to provide treatment after mining accidents, Bergmannsheil today houses 23 highly specialised clinics and specialist departments with 707 beds in total under one roof. More than 2,300 members of staff ensure professional care of approximately 89,000 patients per annum.

Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil is part of the BG Kliniken healthcare group. The group incorporates nine urgent care clinics under the occupational insurance scheme, two clinics for occupational hazards, and two Accident and Emergency centres. With 12,500 members of staff and in excess 550,000 patients, the group is one of the largest clinic associations in Germany. Moreover, Bergmannsheil is part of the Ruhr-Universität Bochum's university clinic (UK RUB). Further information: http://www.bergmannsheil.de

Ruhr-University Bochum

Related Copd Articles:

Treatment seeks to address exacerbations of COPD
A new study finds that delivery of oxygen via high-flow nasal tubes may help patients who experience exacerbations of chronic obstructive pulmonary disease (COPD).
Study reveals surprises concerning COPD and smoking
A new study challenges the widely accepted but oversimplified description of airway inflammation in smokers and patients with chronic obstructive pulmonary disease (COPD).
New guidelines for treatment and management of COPD exacerbations
A multi-disciplinary ERS/ATS task force of chronic obstructive pulmonary disease (COPD) experts has published comprehensive new guidelines on the treatment of COPD exacerbations.
New genetic markers for COPD discovered
In a new Research Letter published in Nature Genetics on Feb.
COPD -- what causes the lungs to lose their ability to heal?
In chronic obstructive pulmonary disease (COPD), the patients' lungs lose their ability to repair damages on their own.
New technology detects COPD in minutes
Pioneering research by Professor Paul Lewis of Swansea University's Medical School into one of the most common lung diseases in the UK, Chronic Obstructive Pulmonary Disease, has led to the development of a new technology that can quickly and easily diagnose and monitor the condition.
COPD exacerbations lead to lung function decline, particularly among those with mild COPD
Acute exacerbations of chronic obstructive pulmonary disease, or COPD, are associated with significant long-term lung function loss, according to research published online, ahead of print in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.
Depression decreases adherence to COPD maintenance medications
A recent study in the Annals of the American Thoracic Society found that in a nationally representative sample of Medicare beneficiaries who were newly diagnosed with COPD, adherence to maintenance medications decreased with new episodes of depression.
Care for COPD: Could more be done?
Meilan Han, M.D., an associate professor of internal medicine at the University of Michigan and the medical director of the U-M Women's Respiratory Health Program, is the lead author on a new report that set out to provide a comprehensive view of COPD care in the US.
COPD symptoms common among smokers, even when undiagnosed
A new study in the New England Journal of Medicine finds that smokers, who wouldn't typically be diagnosed with chronic obstructive pulmonary disease, or COPD, are still showing symptoms consistent with the diagnosis.

Related Copd Reading:

The COPD Solution: A Proven 10-Week Program for Living and Breathing Better with Chronic Lung Disease
by Dawn Lesley Fielding (Author)

COPD For Dummies
by Kevin Felner (Author), Meg Schneider (Author)

The Complete Guide to Understanding and Living with COPD: From A COPDer's Perspective
by R. D. Martin (Author)

Live Your Life With COPD- 52 Weeks of Health, Happiness and Hope
by Jane M Martin (Author)

Natural Therapies for Emphysema and COPD: Relief and Healing for Chronic Pulmonary Disorders
by Robert J. Green Jr. (Author)

COPD: Answers to Your Questions
by MD Donald A. Mahler (Author)

COPD: The Eat to Breathe Plan to Feeling Better
by Teri L. Pizza (Author)

2017 Pocket Guide to COPD Diagnosis, Management and Prevention: A Guide for Healthcare Professionals
by Global Initiative for Chronic Obstructive Lung Disease (Author)

The 100 Most Powerful Affirmations for COPD: Condition Your Mind to Breathe Easy and Live a Beautiful Quality of Life
by WorldAffirmations.com

Breathe Easy: Relieving the Symptoms of Chronic Lung Disease
by Donald A. Mahler MD (Author)

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Dying Well
Is there a way to talk about death candidly, without fear ... and even with humor? How can we best prepare for it with those we love? This hour, TED speakers explore the beauty of life ... and death. Guests include lawyer Jason Rosenthal, humorist Emily Levine, banker and travel blogger Michelle Knox, mortician Caitlin Doughty, and entrepreneur Lux Narayan.
Now Playing: Science for the People

#492 Flint Water Crisis
This week we dig into the Flint water crisis: what happened, how it got so bad, what turned the tide, what's still left to do, and the mix of science, politics, and activism that are still needed to finish pulling Flint out of the crisis. We spend the hour with Dr Mona Hanna-Attisha, a physician, scientist, activist, the founder and director of the Pediatric Public Health Initiative, and author of the book "What the Eyes Don't See: A Story of Crisis, Resistance, and Hope in an American City".